Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies (IMMEDIATE): a pilot study

Trial Profile

Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies (IMMEDIATE): a pilot study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Dermatomyositis; Muscular disorders; Myositis; Polymyositis
  • Focus Therapeutic Use
  • Acronyms IMMEDIATE
  • Sponsors CSL Behring
  • Most Recent Events

    • 25 Oct 2020 Status changed from recruiting to completed as per results published in the Rheumatology.
    • 25 Oct 2020 Results published in the Rheumatology
    • 02 Jul 2019 According to an abstract presented at the 5th Congress of the European Academy of Neurology, 20 patients have been included in this study:dermatomyositis (n=9), non-specific myositis/overlap myositis (n=5), immune-mediated necrotizing myopathy (n=5), and anti-synthetase syndrome (n=1). Primary and secondary endpoints results will be presented at the conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top